# Vironexis Biotherapeutics

Source: https://onco.cc/companies/vironexis-biotherapeutics/  
OnCo record `vironexis-biotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vironexis Biotherapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the AAV-delivered T-cell engager gene therapies VNX-101 and VNX-202 in acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma and advanced solid tumours.

## Summary

Vironexis Biotherapeutics is a clinical-stage biotechnology company developing AAV-delivered, in vivo T-cell engager gene therapies on its TransJoin platform, given as a single intravenous dose. Its lead programme VNX-101 is in phase 1/2 for CD19-positive leukaemias and lymphomas, with VNX-202 for HER2-positive cancers. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06533579 (phase 1/2, Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)) and NCT07192432 (phase 1/2, Gene Therapy for HER-Positive Cancer (SENTRY-HER2)). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Vironexis Biotherapeutics Inc.
- Tags: ctgov-sponsor
- HQ: San Diego, California
- Type: biotech
- Website: https://vironexis.com

## Sources

- Official website: https://vironexis.com
- ClinicalTrials.gov: trials led by Vironexis Biotherapeutics: https://clinicaltrials.gov/search?lead=Vironexis%20Biotherapeutics%20Inc.

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- trials: [Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)](https://onco.cc/trials/nct06533579/), [Gene Therapy for HER-Positive Cancer (SENTRY-HER2)](https://onco.cc/trials/nct07192432/)

---
JSON: https://onco.cc/api/v1/entities/vironexis-biotherapeutics.json